1. Home
  2. QNC vs ALT Comparison

QNC vs ALT Comparison

Compare QNC & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

QNC

Quantum eMotion Corp. Common Shares

N/A

Current Price

$2.81

Market Cap

434.7M

Sector

N/A

ML Signal

N/A

Logo Altimmune Inc.

ALT

Altimmune Inc.

HOLD

Current Price

$2.65

Market Cap

421.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QNC
ALT
Founded
2007
1997
Country
Canada
United States
Employees
5
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
434.7M
421.5M
IPO Year
2026
2005

Fundamental Metrics

Financial Performance
Metric
QNC
ALT
Price
$2.81
$2.65
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$17.67
AVG Volume (30 Days)
476.0K
4.4M
Earning Date
04-28-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
25.37
EPS
N/A
N/A
Revenue
N/A
$41,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
105.00
52 Week Low
$1.90
$2.58
52 Week High
$3.41
$7.73

Technical Indicators

Market Signals
Indicator
QNC
ALT
Relative Strength Index (RSI) 52.42 29.54
Support Level $2.15 N/A
Resistance Level $2.96 $4.25
Average True Range (ATR) 0.22 0.17
MACD 0.02 -0.06
Stochastic Oscillator 76.61 7.41

Price Performance

Historical Comparison
QNC
ALT

About QNC Quantum eMotion Corp. Common Shares

Quantum eMotion Inc is dedicated to developing of a new generation of quantum-safe encryption for the quantum computing age. It is a developer of a new generation of cryptographic solutions under the acquisition of licenses. It allows clients and partners to develop secure quantum-safe encryption that can protect anything from consumer and enterprise devices like mobile phones, computers, the Internet of Things, and networking equipment to demanding cloud-based applications, servers, and military devices.

About ALT Altimmune Inc.

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: